We’re proud to announce our continued partnership with Neoplas Med GmbH, underscoring our dedication to advancing healthcare innovation globally. Building on our investments in 2022 and 2023, Niterra Ventures Company has invested an additional $18 million in Neoplas Med, bringing our total support to $25 million. This latest funding round aims to accelerate the international expansion of their revolutionary wound care technology, the kINPen® MED.
This innovative argon cold plasma device has already redefined wound care, enabling over 500,000 treatments worldwide. Clinical studies reveal it reduces healing time by up to 50% without side effects or the development of resistance. Neoplas Med’s plasma jet therapy has become a game-changer for treating infected and chronic wounds, offering patients a nearly painless and highly effective solution.
The funds will support Neoplas Med in scaling operations and bringing the kINPen® MED to new markets, including the United States, Europe, and the Middle East. Already a leading innovator in cold plasma therapy, Neoplas Med is the only European manufacturer certified under the European Medical Device Regulation (MDR) for cold plasma products.
“We are thrilled about the additional investment by Niterra Ventures Company,” said Ulrike Sailer, CEO of Neoplas Med. “This partnership unlocks opportunities to further develop our technology platform, create new products, and expand into untapped markets, all while strengthening high-tech employment opportunities.”
Neoplas Med, founded as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP), has become a global leader in leveraging argon cold plasma for advanced wound care. In Germany alone, 75% of university clinics, along with numerous hospitals and medical practices, use this groundbreaking therapy. Neoplas Med’s focus on precision, safety, and efficacy has made the kINPen® MED a trusted solution for healthcare providers worldwide.
At Niterra Ventures, we are dedicated to harnessing technologies to improve lives globally. “The impact of Neoplas Med’s kINPen® argon cold plasma therapy is undeniable, and our continued investment represents a shared vision to advance healthcare,” said Dirk Schapeler, President of Niterra Ventures Company. “This collaboration is a cornerstone of our mission to drive innovation in medical technology, cleantech, energy, and IoT sectors.”
As Neoplas Med scales its groundbreaking technology to new regions, Niterra Ventures remains committed to supporting innovations that redefine healthcare and improve quality of life. Together, we’re breaking barriers in wound care and setting the stage for a healthier future.
Stay tuned for more updates as we work to expand kINPen® MED’s reach and deliver impactful solutions to patients worldwide.
‍
